These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor. Goubin F; Ducommun B Oncogene; 1995 Jun; 10(12):2281-7. PubMed ID: 7784076 [TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Orend G; Hunter T; Ruoslahti E Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134 [TBL] [Abstract][Full Text] [Related]
9. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932 [TBL] [Abstract][Full Text] [Related]
10. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes. Lacy S; Whyte P Oncogene; 1997 May; 14(20):2395-406. PubMed ID: 9188854 [TBL] [Abstract][Full Text] [Related]
11. Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells. Poon RY; Hunter T Oncogene; 1998 Mar; 16(10):1333-43. PubMed ID: 9546435 [TBL] [Abstract][Full Text] [Related]
12. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Rao S; Lowe M; Herliczek TW; Keyomarsi K Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471 [TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of a novel p21(Cip1/Waf1)-interacting zinc finger protein, ciz1. Mitsui K; Matsumoto A; Ohtsuka S; Ohtsubo M; Yoshimura A Biochem Biophys Res Commun; 1999 Oct; 264(2):457-64. PubMed ID: 10529385 [TBL] [Abstract][Full Text] [Related]
14. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R Oncogene; 1999 Jul; 18(30):4313-25. PubMed ID: 10439039 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Gong J; Ammanamanchi S; Ko TC; Brattain MG Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668 [TBL] [Abstract][Full Text] [Related]
16. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Li Y; Jenkins CW; Nichols MA; Xiong Y Oncogene; 1994 Aug; 9(8):2261-8. PubMed ID: 7913544 [TBL] [Abstract][Full Text] [Related]
17. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Lu Y; Yamagishi N; Yagi T; Takebe H Oncogene; 1998 Feb; 16(6):705-12. PubMed ID: 9488034 [TBL] [Abstract][Full Text] [Related]
18. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints. Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036 [TBL] [Abstract][Full Text] [Related]
19. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. Sekiguchi T; Hunter T Oncogene; 1998 Jan; 16(3):369-80. PubMed ID: 9467962 [TBL] [Abstract][Full Text] [Related]
20. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. Ono T; Kitaura H; Ugai H; Murata T; Yokoyama KK; Iguchi-Ariga SM; Ariga H J Biol Chem; 2000 Oct; 275(40):31145-54. PubMed ID: 10878006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]